Clinical Trials Logo

Choroidal Neovascularization clinical trials

View clinical trials related to Choroidal Neovascularization.

Filter by:

NCT ID: NCT03897192 Completed - Clinical trials for Punctate Inner Choroidopathy

Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis

Start date: October 1, 2018
Phase:
Study type: Observational

To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).

NCT ID: NCT03844074 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

NCT ID: NCT03834753 Completed - Clinical trials for Age-related Macular Degeneration

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: June 25, 2019
Phase: Phase 3
Study type: Interventional

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

NCT ID: NCT03793400 Completed - Clinical trials for Choroidal Neovascularization

Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Start date: March 13, 2018
Phase:
Study type: Observational

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

NCT ID: NCT03409250 Completed - Clinical trials for Age Related Macular Degeneration

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Start date: June 2011
Phase: Phase 4
Study type: Interventional

This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia. Newly diagnosed and active CNVs due to myopia are treated with one intravitreal injection of Ranibizumab 0.5mg (Lucentis) at baseline. During the follow up period of 12 months monthly ophthalmological examinations including best corrected visual acuity (BCVA) and high resolution spectral-domain optical coherence tomography (SD-OCT) assessments are performed. Detection of persisting or new signs of CNV activity at OCT triggers ranibizumab re-treatment considering that any ranibizumab injections can maximally be applied as often as monthly.

NCT ID: NCT03393767 Completed - Clinical trials for Age Related Macular Degeneration

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Start date: December 2010
Phase: Phase 4
Study type: Interventional

The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at baseline as assessed by weekly high resolution optical coherence tomography (OCT). Detection of persisting or new signs of CNV activity at OCT triggers further ranibizumab treatments considering that any ranibizumab injections can maximally be applied as often as 2-weekly.

NCT ID: NCT03070717 Completed - Pathologic Myopia Clinical Trials

High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

HELP
Start date: June 12, 2014
Phase:
Study type: Observational

This research project intends to observe patients with high myopia who show pathological retinal changes, in order to evaluate more data on the risk factors for developing mCNV within this research project population in Germany.

NCT ID: NCT03042871 Completed - Clinical trials for Choroidal Neovascularization

Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization

SMILE
Start date: April 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy (times of injection, change of visual acuity and Cva/ I) and safety (macular visual function and choroidal thickness) of different dosing of ranibizumab intravitreal injection (1+PRN vs. 3+PRN) in treating with pathological myopia choroidal neovascularization (PM-CNV).

NCT ID: NCT03038880 Completed - Clinical trials for Macular Degeneration, Age-Related

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

STAIRWAY
Start date: January 27, 2017
Phase: Phase 2
Study type: Interventional

This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.

NCT ID: NCT03024424 Completed - Clinical trials for Age-Related Macular Degeneration

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

Start date: March 2016
Phase: N/A
Study type: Interventional

The goals of this study are: To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in personal analysis of risk for age-related macular degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal neovascularization (CNV).